Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Mitch DowsettRichard Peto

Abstract

To conduct meta-analyses of randomized trials of aromatase inhibitors (AIs) compared with tamoxifen either as initial monotherapy (cohort 1) or after 2 to 3 years of tamoxifen (cohort 2). Data submitted to the Early Breast Cancer Trialists' Collaborative Group were used in separate meta-analyses of two cohorts. Primary analyses involve postmenopausal women with tumors reported to be estrogen receptor positive. Log-rank P values are two-sided. Cohort 1 comprised 9,856 patients with a mean of 5.8 years of follow-up. At 5 years, AI therapy was associated with an absolute 2.9% (SE = 0.7%) decrease in recurrence (9.6% for AI v 12.6% for tamoxifen; 2P < .00001) and a nonsignificant absolute 1.1% (SE = 0.5%) decrease in breast cancer mortality (4.8% for AI v 5.9% for tamoxifen; 2P = .1). Cohort 2 comprised 9,015 patients with a mean of 3.9 years of follow-up. At 3 years from treatment divergence (ie, approximately 5 years after starting hormonal treatment), AI therapy was associated with an absolute 3.1% (SE = 0.6%) decrease in recurrence (5.0% for AI v 8.1% for tamoxifen since divergence; 2P < .00001) and an absolute 0.7% (SE = 0.3%) decrease in breast cancer mortality (1.7% for AI v 2.4% for tamoxifen since divergence; 2P = .02). Th...Continue Reading

References

Dec 29, 1988·The New England Journal of Medicine·UNKNOWN Early Breast Cancer Trialists' Collaborative Group
Feb 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jürgen GeislerPer Eystein Lønning
Nov 29, 2002·Nature Medicine·Mitch Dowsett, Anthony Howell
Jun 13, 2003·The New England Journal of Medicine·Ian E Smith, Mitch Dowsett
Mar 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M Carolina GutierrezMitch Dowsett
Apr 13, 2005·Lancet·Jack Cuzick
Jun 9, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F BoccardoP Sismondi
Sep 5, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·V Craig Jordan
Jan 4, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan S CoatesAron Goldhirsch
Feb 9, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nancy U Lin, Eric P Winer
May 2, 2008·Expert Opinion on Investigational Drugs·Per Eystein Lønning, Jürgen Geisler

❮ Previous
Next ❯

Citations

Feb 1, 2012·Breast Cancer Research and Treatment·Rainer GirgertCarsten Gründker
Apr 3, 2013·Breast Cancer Research and Treatment·N Lynn HenryDavid A Flockhart
Oct 1, 2013·The Breast : Official Journal of the European Society of Mastology·Maria Vittoria DieciFabrice Andre
Oct 1, 2013·The Breast : Official Journal of the European Society of Mastology·Kathrin Strasser-WeipplPaul E Goss
Oct 1, 2013·The Breast : Official Journal of the European Society of Mastology·James N Ingle
Nov 2, 2013·The Breast : Official Journal of the European Society of Mastology·Arjun Mehta, Debu Tripathy
Oct 8, 2013·European Urology·Hagen F Kennecke, Mira Keyes
Jan 25, 2011·Lancet·R Charles Coombes, Lucy S Kilburn
Jan 1, 2012·BoneKEy Reports·Jean-Jacques Body
May 3, 2013·Journal of Human Genetics·James N Ingle
Jul 25, 2013·Nature Reviews. Clinical Oncology·Michail Ignatiadis, Christos Sotiriou
Oct 9, 2013·Nature Reviews. Clinical Oncology·Kathrin Strasser-Weippl, Paul E Goss
Jun 7, 2011·The New England Journal of Medicine·Nancy E Davidson, Thomas W Kensler
Jun 7, 2011·The New England Journal of Medicine·Paul E GossUNKNOWN NCIC CTG MAP.3 Study Investigators
Aug 17, 2011·Proceedings of the National Academy of Sciences of the United States of America·Anders CarlssonCarl A K Borrebaeck
Oct 21, 2011·Proceedings of the National Academy of Sciences of the United States of America·Eric A AriaziV Craig Jordan
Oct 15, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M Colleoni, A Giobbie-Hurder
Jul 10, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P E Lønning
Oct 12, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R EastellR E Coleman
Dec 2, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H YamashitaS Kobayashi
Feb 22, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G VialeUNKNOWN BIG 1-98 Collaborative and International Breast Cancer Study Groups
Feb 2, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S AebiA Goldhirsch
Feb 10, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M MalvezziE Negri
Mar 19, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P HadjiA Lipton
Oct 20, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S AebiUNKNOWN ESMO Guidelines Working Group
Mar 14, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F NuzzoF Perrone
May 4, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C Villarreal-GarzaS Verma
Sep 26, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M Colleoni, E Montagna
Oct 3, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P E GossD Tu
Apr 25, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N L HenryD F Hayes
Aug 24, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E SenkusUNKNOWN ESMO Guidelines Working Group
Oct 1, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F AdesM Piccart
Jul 12, 2011·Journal of the National Cancer Institute·Eitan AmirAlberto Ocaña
Aug 24, 2011·Journal of the National Cancer Institute·Shannon PuhallaNancy E Davidson
Nov 9, 2011·Molecular and Cellular Biology·Prashant RajbhandariElaine T Alarid
Dec 6, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matthew P GoetzJames N Ingle
May 16, 2012·Cancer Discovery·Andrea DecensiLeslie G Ford
Jan 20, 2010·Breast Cancer Research : BCR·Mitch DowsettIan E Smith

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.